Abstract:Abstract Virus-like particles (VLPs) are virus-derived structures made up of one or more different molecules with the ability to self-assemble, mimicking the form and size of a virus particle but lacking the genetic material so they are not capable of infecting the host cell. Expression and self-assembly of the viral structural proteins can take place in various living or cell-free expression systems after which the viral structures can be assembled and reconstructed. VLPs are gaining in popularity in the field of preventive medicine and to date, a wide range of VLP-based candidate vaccines have been developed for immunization against various infectious agents, the latest of which is the vaccine against SARS-CoV-2, the efficacy of which is being evaluated. VLPs are highly immunogenic and are able to elicit both the antibody- and cell-mediated immune responses by pathways different from those elicited by conventional inactivated viral vaccines. However, there are still many challenges to this surface display system that need to be addressed in the future. VLPs that are classified as subunit vaccines are subdivided into enveloped and non- enveloped subtypes both of which are discussed in this review article. VLPs have also recently received attention for their successful applications in targeted drug delivery and for use in gene therapy. The development of more effective and targeted forms of VLP by modification of the surface of the particles in such a way that they can be introduced into specific cells or tissues or increase their half-life in the host is likely to expand their use in the future. Recent advances in the production and fabrication of VLPs including the exploration of different types of expression systems for their development, as well as their applications as vaccines in the prevention of infectious diseases and cancers resulting from their interaction with, and mechanism of activation of, the humoral and cellular immune systems are discussed in this review.

[Current research status of virus-like particle vaccine]

Advances in the study of virus-like particles as vaccines

Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers

Virus-like particles as powerful vaccination strategy against human viruses

Recent Progress on the Versatility of Virus-Like Particles

Research Progress of Murine Polyomavirus Virus-like Particle and Its Application in Vaccine Development

Virus-like Particles: Potential Veterinary Vaccine Immunogens.

Virus-like Particle Vaccines and Platforms for Vaccine Development

Biomolecular engineering of virus-like particles aided by computational chemistry methods

Virus-like particles: flexible platforms for vaccine development

Progress in Developing Virus-Like Particle Influenza Vaccines

Progress in developing virus-like particle influenza vaccines.

Virus-like particle-based vaccine development using Escherichia coil expression system

Virus-Like Particle Vaccines Against Respiratory Viruses and Protozoan Parasites.

Yeast-Based Virus-like Particles as an Emerging Platform for Vaccine Development and Delivery

Virus-Like Particle Engineering: From Rational Design to Versatile Applications

Research Progress on Foot-and-mouth Disease Virus Virus-like Particles

Virus-like particles: The new frontier of vaccines for animal viral infections

Virus-like Particles As Nanocarriers for Intracellular Delivery of Biomolecules and Compounds.

Influenza vaccines based on virus-like particles.

Platforms, advances, and technical challenges in virus-like particles-based vaccines